Jill Carroll Net Worth

The estimated Net Worth of Jill Carroll is at least $119 Million dollars as of 1 April 2014. Jill Carroll owns over 103,762 units of Pandion Therapeutics stock worth over $119,475,360 and over the last 11 years Jill sold PAND stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Jill Carroll PAND stock SEC Form 4 insiders trading

Jill has made over 1 trades of the Pandion Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Jill bought 103,762 units of PAND stock worth $1,245,144 on 1 April 2014.

The largest trade Jill's ever made was buying 103,762 units of Pandion Therapeutics stock on 1 April 2014 worth over $1,245,144. On average, Jill trades about 51,881 units every 0 days since 2014. As of 1 April 2014 Jill still owns at least 1,989,598 units of Pandion Therapeutics stock.

You can see the complete history of Jill Carroll stock trades at the bottom of the page.

What's Jill Carroll's mailing address?

Jill's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.

Insiders trading at Pandion Therapeutics

Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol..., and Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.

What does Pandion Therapeutics do?

Complete history of Jill Carroll stock trades at Applied Genetic Technologies Corp and Pandion Therapeutics

Pandion Therapeutics executives and stock owners

Pandion Therapeutics executives and other stock owners filed with the SEC include:

• Capital Management, L.P.Kol...,
  
• Nancy Stagliano,
  Director
• Vikas Goyal,
  See Remarks
• Joanne L. Viney,
  See Remarks
• Partners Gp Viii, L.L.C.Pol...,
  
• Rizzuto Carlo,
  Director
• Jill Carroll,
  Director
• Katina Dorton,
  Director
• Donald Frail,
  Director
• Christopher Fuglesang,
  Director
• Gregg Beloff,
  See Remarks
• Alan L Crane,
  Director
• Mitchell Mutz,
  Director
• Eric D Larson,
  Vice President, Finance
• Daniel J. Becker,
  Director
• Rahul Kakkar,
  Chief Executive Officer
• Plc Gsk,
  Director
• John Sundy,
  Chief Medical Officer
• Edward D. Freedman,
  Chief Operating Officer